Replicating predictive serum correlates of greater translocator protein distribution volume in brain.
Journal
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
ISSN: 1740-634X
Titre abrégé: Neuropsychopharmacology
Pays: England
ID NLM: 8904907
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
25
07
2019
accepted:
11
10
2019
revised:
24
09
2019
pubmed:
5
11
2019
medline:
24
6
2021
entrez:
5
11
2019
Statut:
ppublish
Résumé
Greater activation of glia, a key component of neuroinflammation, is an important process to target in neuropsychiatric illnesses. However, the magnitude of gliosis varies across cases so low-cost predictors are needed to stratify subjects for clinical trials. Here, several such blood serum measures were assessed in relation to TSPO V
Identifiants
pubmed: 31683271
doi: 10.1038/s41386-019-0561-y
pii: 10.1038/s41386-019-0561-y
pmc: PMC7162884
doi:
Substances chimiques
Receptors, GABA
0
TSPO protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
925-931Subventions
Organisme : CIHR
ID : GSD-157948
Pays : Canada
Organisme : CIHR
ID : MOP-136955
Pays : Canada
Références
WHO. 169 (World Health Organization, Geneva, Switzerland, 2001).
Attwells S, Setiawan E, Wilson AA, Rusjan PM, Mizrahi R, Miler L, et al. Inflammation in the neurocircuitry of obsessive-compulsive disorder. JAMA Psychiatry. 2017;74:833–40.
doi: 10.1001/jamapsychiatry.2017.1567
Setiawan E, Attwells S, Wilson AA, Mizrahi R, Rusjan PM, Miler L, et al. Association of translocator protein total distribution volume with duration of untreated major depressive disorder: a cross-sectional study. Lancet Psychiatry. 2018;5:339–47.
doi: 10.1016/S2215-0366(18)30048-8
Richards EM, Zanotti-Fregonara P, Fujita M, Newman L, Farmer C, Ballard ED, et al. PET radioligand binding to translocator protein (TSPO) is increased in unmedicated depressed subjects. EJNMMI Res. 2018;8:57.
doi: 10.1186/s13550-018-0401-9
Li H, Sagar AP, Keri S. Translocator protein (18kDa TSPO) binding, a marker of microglia, is reduced in major depression during cognitive-behavioral therapy. Prog neuro-Psychopharmacol Biol Psychiatry 2018;83:1–7.
doi: 10.1016/j.pnpbp.2017.12.011
Hickman S, Izzy S, Sen P, Morsett L, El Khoury J. Microglia in neurodegeneration. Nat Neurosci 2018;21:1359–69.
doi: 10.1038/s41593-018-0242-x
Setiawan E, Wilson AA, Mizrahi R, Rusjan PM, Miler L, Rajkowska G, et al. Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry. 2015;72:268–75.
doi: 10.1001/jamapsychiatry.2014.2427
Holmes SE, Hinz R, Conen S, Gregory CJ, Matthews JC, Anton-Rodriguez JM, et al. Elevated translocator protein in anterior cingulate in major depression and a role for inflammation in suicidal thinking: a positron emission tomography study. Biol Psychiatry 2018;83:61–9.
doi: 10.1016/j.biopsych.2017.08.005
Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci. 2007;8:57–69.
doi: 10.1038/nrn2038
Betlazar C, Harrison-Brown M, Middleton RJ, Banati R, Liu GJ. Cellular sources and regional variations in the expression of the neuroinflammatory marker translocator protein (TSPO) in the normal brain. Int J Mol Sci. 2018;19:pii: E2707.
doi: 10.3390/ijms19092707
Banati RB, Myers R, Kreutzberg GW. PK (‘peripheral benzodiazepine’)–binding sites in the CNS indicate early and discrete brain lesions: microautoradiographic detection of [3H]PK11195 binding to activated microglia. J Neurocytol. 1997;26:77–82.
doi: 10.1023/A:1018567510105
Martin A, Boisgard R, Theze B, Van Camp N, Kuhnast B, Damont A, et al. Evaluation of the PBR/TSPO radioligand [(18)F]DPA-714 in a rat model of focal cerebral ischemia. J Cereb Blood Flow Metab: Off J Int Soc Cereb Blood Flow Metab. 2010;30:230–41.
doi: 10.1038/jcbfm.2009.205
Narayanaswami V, Dahl K, Bernard-Gauthier V, Josephson L, Cumming P, Vasdev N. Emerging PET radiotracers and targets for imaging of neuroinflammation in neurodegenerative diseases: outlook beyond TSPO. Mol imaging 2018;17:1536012118792317.
doi: 10.1177/1536012118792317
Horti AG, Naik R, Foss CA, Minn I, Misheneva V, Du Y, et al. PET imaging of microglia by targeting macrophage colony-stimulating factor 1 receptor (CSF1R). Proceedings of the National Academy of Sciences of the United States of America. 2019.
Galasko D, Montine TJ. Biomarkers of oxidative damage and inflammation in Alzheimer’s disease. Biomark Med. 2010;4:27–36.
doi: 10.2217/bmm.09.89
Wang AK, Miller BJ. Meta-analysis of cerebrospinal fluid cytokine and tryptophan catabolite alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder, and depression. Schizophrenia Bull 2018;44:75–83.
doi: 10.1093/schbul/sbx035
Pulli B, Chen JW. Imaging neuroinflammation - from bench to bedside. J Clin Cell Immunol. 2014;5:pii: 226.
Minghetti L, Polazzi E, Nicolini A, Creminon C, Levi G. Up-regulation of cyclooxygenase-2 expression in cultured microglia by prostaglandin E2, cyclic AMP and non-steroidal anti-inflammatory drugs. Eur J Neurosci. 1997;9:934–40.
doi: 10.1111/j.1460-9568.1997.tb01444.x
Akanuma S, Higuchi T, Higashi H, Ozeki G, Tachikawa M, Kubo Y, et al. Transporter-mediated prostaglandin E(2) elimination across the rat blood-brain barrier and its attenuation by the activation of N-methyl-D-aspartate receptors. Drug Metab pharmacokinetics. 2014;29:387–93.
doi: 10.2133/dmpk.DMPK-14-RG-004
Tachikawa M, Hosoya K, Terasaki T. Pharmacological significance of prostaglandin E2 and D2 transport at the brain barriers. Adv Pharm. 2014;71:337–60.
doi: 10.1016/bs.apha.2014.06.006
Banks WA. The blood-brain barrier in neuroimmunology: tales of separation and assimilation. Brain Behav Immun. 2015;44:1–8.
doi: 10.1016/j.bbi.2014.08.007
Hagen AA, Gerber JN, Sweeley CC, White RP, Robertson JT. Levels and disappearance of prostaglandin F2alpha in cerebral spinal fluid: a clinical and experimental study. Stroke 1977;8:672–5.
doi: 10.1161/01.STR.8.6.672
Kalinski P. Regulation of immune responses by prostaglandin E2. J Immunol 2012;188:21–8.
doi: 10.4049/jimmunol.1101029
Ressler KJ, Mayberg HS. Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. Nat Neurosci 2007;10:1116–24.
doi: 10.1038/nn1944
Drevets WC, Price JL, Furey ML. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct. 2008;213:93–118.
doi: 10.1007/s00429-008-0189-x
Williams LM. Precision psychiatry: a neural circuit taxonomy for depression and anxiety. Lancet Psychiatry. 2016;3:472–80.
doi: 10.1016/S2215-0366(15)00579-9
Adams KH, Hansen ES, Pinborg LH, Hasselbalch SG, Svarer C, Holm S, et al. Patients with obsessive-compulsive disorder have increased 5-HT2A receptor binding in the caudate nuclei. Int J Neuropsychopharmacol. 2005;8:391–401.
doi: 10.1017/S1461145705005055
Wong DF, Brasic JR, Singer HS, Schretlen DJ, Kuwabara H, Zhou Y, et al. Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET. Neuropsychopharmacology. 2008;33:1239–51.
doi: 10.1038/sj.npp.1301528
Saxena S, Brody AL, Schwartz JM, Baxter LR. Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder. Br. J. Psychiatry. 1998;35:26–37.
Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.
doi: 10.1136/jnnp.23.1.56
Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, et al. The yale-brown obsessive compulsive scale. II. Validity. Arch Gen Psychiatry. 1989;46:1012–6.
doi: 10.1001/archpsyc.1989.01810110054008
Rusjan P, Mamo D, Ginovart N, Hussey D, Vitcu I, Yasuno F, et al. An automated method for the extraction of regional data from PET images. Psychiatry Res. 2006;147:79–89.
doi: 10.1016/j.pscychresns.2006.01.011
Rusjan PM, Wilson AA, Bloomfield PM, Vitcu I, Meyer JH, Houle S, et al. Quantitation of translocator protein binding in human brain with the novel radioligand [18F]-FEPPA and positron emission tomography. J Cereb Blood Flow Metab. 2011;31:1807–16.
doi: 10.1038/jcbfm.2011.55
Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med. 2000;6:1399–402.
doi: 10.1038/82219
Henry CJ, Huang Y, Wynne A, Hanke M, Himler J, Bailey MT, et al. Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. J Neuroinflammation. 2008;5:15.
doi: 10.1186/1742-2094-5-15
Coughlin JM, Wang Y, Ambinder EB, Ward RE, Minn I, Vranesic M, et al. In vivo markers of inflammatory response in recent-onset schizophrenia: a combined study using [(11)C]DPA-713 PET and analysis of CSF and plasma. Transl Psychiatry. 2016;6:e777.
doi: 10.1038/tp.2016.40
Sandiego CM, Gallezot JD, Pittman B, Nabulsi N, Lim K, Lin SF, et al. Imaging robust microglial activation after lipopolysaccharide administration in humans with PET. Proc Natl Acad Sci USA. 2015;112:12468–73.
doi: 10.1073/pnas.1511003112
Hannestad J, DellaGioia N, Gallezot JD, Lim K, Nabulsi N, Esterlis I, et al. The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: a [(1)(1)C]PBR28 PET study. Brain Behav Immun. 2013;33:131–8.
doi: 10.1016/j.bbi.2013.06.010
Saito O, Svensson CI, Buczynski MW, Wegner K, Hua XY, Codeluppi S, et al. Spinal glial TLR4-mediated nociception and production of prostaglandin E(2) and TNF. Br J Pharmacol. 2010;160:1754–64.
doi: 10.1111/j.1476-5381.2010.00811.x
Dong Y, Benveniste EN. Immune function of astrocytes. Glia 2001;36:180–90.
doi: 10.1002/glia.1107